Trials / Terminated
TerminatedNCT00148018
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (planned)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.
Detailed description
The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2005-03-01
- First posted
- 2005-09-07
- Last updated
- 2008-07-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00148018. Inclusion in this directory is not an endorsement.